EN DE
STOCK COMPARISON

Kaken Pharmaceutical Co. vs Merck KGaA: Fair Value & Quality

Both stocks run through our valuation models. Here is how Kaken Pharmaceutical Co. (KKPCF) and Merck KGaA (MRK) compare, as of Sep 24, 2026.

As of Sep 24, 2026, Fair Value Calculator sees Merck KGaA as the less overvalued of the two: Kaken Pharmaceutical Co. trades at $26.00 versus a fair value of $7.90 (-70%), while Merck KGaA trades at €133 versus €109 (-18%).
Kaken Pharmaceutical Co.
KKPCF · USD · Health Care
-70%
upside to fair value
overvalued
Price$26.00
Fair Value$7.90
Quality43/100
Merck KGaA
MRK.XETRA · EUR · Health Care
-18%
upside to fair value
overvalued
Price€133
Fair Value€109
Quality62/100
Get comparisons like this free by email every month: the most undervalued quality stocks.

Head-to-head numbers

Green is the better side of a row, red the weaker one (for valuation multiples: lower = cheaper). Grey rows are for reference only and are not scored.

betterweakerfor reference, not scored

Kaken Pharmaceutical Co.Merck KGaA
Valuation
288.9×P/E (TTM)24.1×
2.04×P/S (TTM)3.14×
1.05×P/B2.30×
46.0×EV/EBITDA12.9×
n/aPEG2.76×
−69.6%Fair value upside−18.2%
4.6%Dividend yield1.7%
$190Dividend per share€2.20
Profitability
-8%Operating margin18%
n/aEBIT margin trend (5Y)1.07×
1%Return on equity9%
-0%Return on assets5%
Growth
7%Revenue growth (YoY)-3%
2.0%Avg. growth/yr (3Y)-1.7%
0.6%Avg. growth/yr (5Y)3.8%
−25.8%Value creation/yr+7.3%
Balance & size
n/aInterest coverage (EBIT/interest)15.5×
n/aDebt / equity0.36×
$986MMarket cap$66B
weakGrowth qualitymixed

Merck KGaA leads: 4 to 8 metric wins.

n/a = not meaningfully computable, for example with negative equity.

Quality in detail

The quality score, broken down into the same factor families as on the stock page, 0 to 100 per family.

Kaken Pharmaceutical Co.of which business quality 44 · market factors 57 Merck KGaAof which business quality 61 · market factors 65
ProfitabilityMargins and returns on capital today
26
41
Quality GrowthAre margins and returns improving?
4
40
CashflowEarnings quality: real cash, not paper profit
0
57
Fin. StrengthBalance sheet, leverage, solvency risk
81
76
InvestmentDisciplined investing over empire-building
87
80
Low VolatilityCalm price path (market factor)
87
72
MomentumPrice trend over the last 3–12 months (market factor)
41
59
52W MomentumDistance to the 52-week high (market factor)
49
65
Net IssuanceShare count: buybacks or dilution?
84
82

What the models say

How far the median fair value (base case) per model family sits from the current price, in percent. The amount in the currency of the trading venue is shown underneath.

above the price, more than 15% above close to the price, 85% to 115% of the price below the price, more than 15% below

Model familyKaken Pharmaceutical Co.Price $26.00Merck KGaAPrice €133
DCF Models-70%below the price$7.90-19%below the price€107
Earnings-Based-92%below the price$1.98-60%below the price€53.25
Dividend Discountn/a-69%below the price€40.71
Multiples-82%below the price$4.64-11%close to the price€118
Asset-Based-58%below the price$10.97-67%below the price€44.06
Growth DCFn/a-29%below the price€94.57
Economic Profit-63%below the price$9.73-50%below the price€66.44
Growth Earnings-85%below the price$3.95-13%close to the price€115
Minimum-92%below the price$1.98-69%below the price€40.71
Maximum-58%below the price$10.97-11%close to the price€118
Median-76%below the price$6.27-39%below the price€80.50
Geometric mean-79%below the price$5.59-45%below the price€73.75

Minimum, maximum, median and geometric mean refer to the family values in this table. Geometric because deviations are ratios: half the price and twice the price average to 100%, not 125%.

Kaken Pharmaceutical Co.: 9 of 9 models see the stock below the current price.

Merck KGaA: 22 of 26 models see the stock below the current price.

Scenario ranges

From our cautious bear scenario to the optimistic bull scenario. The white tick is the current price (value above it), the green tick the fair value (value below it): if the price sits left of the fair value, there is room to rise.

Kaken Pharmaceutical Co.
Price $26.00
Fair Value $7.90
Bear $5.92Bull $9.87
Merck KGaA
Price €133
Fair Value €109
Bear €59.91Bull €150

Compare two other stocks

Tap a field and type again, ticker or company name.

Free, no sign-up

Ranked within their sector

Where each stock sits within its sector peer group. Band = middle 50% of peers, tick = median, dot = this stock.

Kaken Pharmaceutical Co. · Health Care

Quality score43 · below median
Fair value upside-70% · bottom 25%

Merck KGaA · Health Care

Quality score62 · above median
Fair value upside-18% · above median

Bottom line

As of Sep 24, 2026, Fair Value Calculator sees Merck KGaA as the less overvalued of the two: Kaken Pharmaceutical Co. trades at $26.00 versus a fair value of $7.90 (-70%), while Merck KGaA trades at €133 versus €109 (-18%).

Merck KGaA has the higher quality score (62/100).

Open Merck KGaA live analysis →
Kaken Pharmaceutical Co. · Merck KGaA

More comparisons

Popular match-ups from the same sectors, all with fair value and quality score.

Related to Kaken Pharmaceutical Co.

Microsoft vs NvidiaApple vs MicrosoftNvidia vs Taiwan Semiconductor ManufacturingApple vs Taiwan Semiconductor Manufacturing

Related to Merck KGaA

Alphabet Inc Class C vs Meta PlatformsCisco Systems vs NvidiaMicrosoft vs Taiwan Semiconductor ManufacturingApple vs Cisco Systems
Free · Top-25 report

See the undervalued quality stocks every month

Just your email for the monthly Top-25 report of the most undervalued quality stocks, with fair value, quality and price target. Plus 14 days of Pro to try, no card.

Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click. Not financial advice.

A model-based valuation snapshot from 26 models. Values change with price and fundamentals; the date shown above applies.